Advertisement
Screener

GENZYME CORP Patents: Applications Pending, 2023

GENZYME CORP Patent Applications Pending

86 applications still open at the USPTO, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.

  • 2023-12-28: Application 18399364; Invention GENE EDITING OF DEEP INTRONIC MUTATIONS; Applicant Genzyme Corporation; Status Response to Non-Final Office Action Entered and Forwarded to Examiner.
  • 2023-12-27: Application 63614973; Invention DRUG FORMULATIONS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL) -3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE; Applicant Genzyme Corporation; Status Provisional Application Expired.
  • 2023-12-21: Application 63613221; Invention CRYSTALLINE FORM OF AN ISOXAZOLIDINE DERIVATIVE; Applicant GENZYME CORPORATION; Status Provisional Application Expired.
  • 2023-12-20: Application PCTUS2023084992; Invention ANTI-PD-1 4-1BB BINDING PROTEINS; Applicant GENZYME CORPORATION; Status RO PROCESSING COMPLETED-PLACED IN STORAGE.
FiledApplicationInventionApplicantStatusPublished asInventor nameInventor countryExaminer
2023-12-2818399364GENE EDITING OF DEEP INTRONIC MUTATIONSGenzyme CorporationResponse to Non-Final Office Action Entered and Forwarded to ExaminerUS20240197837A1
Guoxiang RUAN
Abraham SCARIA
United States
United States
TATGE, LEXUS MARC
2023-12-2763614973DRUG FORMULATIONS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL) -3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILEGenzyme CorporationProvisional Application Expired
Jerome Arigon
Marilyn Calderone
Brigitte Illel
France
France
France
2023-12-2163613221CRYSTALLINE FORM OF AN ISOXAZOLIDINE DERIVATIVEGENZYME CORPORATIONProvisional Application Expired
Helena MORA RADÓ
Natascha ENGEL
Germany
Germany
2023-12-20PCTUS2023084992ANTI-PD-1 4-1BB BINDING PROTEINSGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
MARTA AMARAL
CHRISTIAN BEIL
LAURENCE BERTHOU-SOULIÉ
JOERG BIRKENFELD
BÉATRICE CAMERON
MARGOT CUCCHETTI
TARIK DABDOUBI
KLERVI DESRUMEAUX
FANGYONG DU
NORBERT FURTMANN
SORAYA HOELPER
YAN LI
GUIZHONG LIU
PETER PEIZHI LUO
ERCOLE RAO
INGRID SASSOON
MARION SCHNEIDER
FABIENNE SOUBRIER
EMMANUELLE VIGNE
Germany
Germany
France
Germany
France
France
France
France
United States
Germany
Germany
United States
United States
United States
Germany
France
Germany
France
France
2023-12-2018389951ANTI-PD-1×4-1BB BINDING PROTEINSGenzyme CorporationNon Final Action MailedUS20240262923A1
Marta AMARAL
Christian BEIL
Laurence BERTHOU-SOULIÉ
Joerg BIRKENFELD
Béatrice CAMERON
Margot CUCCHETTI
Tarik DABDOUBI
Klervi DESRUMEAUX
Fangyong DU
Norbert FURTMANN
Soraya HOELPER
Yan LI
Guizhong LIU
Peter Peizhi LUO
Ercole RAO
Ingrid SASSOON
Marion SCHNEIDER
Fabienne SOUBRIER
Emmanuelle VIGNE
Germany
Germany
France
Germany
France
France
France
France
United States
Germany
Germany
United States
United States
United States
Germany
France
Germany
France
France
GODDARD, LAURA B
2023-12-1918545029DRUG FORMULATIONS OF (R)-1-(1-ACRYLOYLPIPERIDIN-3-YL)-4-AMINO-3-(4-PHENOXYPHENYL)-1H-IMIDAZO[4,5-C]PYRIDIN-2(3H)-ONEGenzyme CorporationNotice of Allowance Mailed -- Application Received in Office of PublicationsUS20240238267A1
Marilyn Calderone
Caroline Viault
France
France
JACKSON, SHAWQUIA
2023-12-1863611673IL-12 LOSS OF POTENCY MUTEINSGENZYME CORPORATIONProvisional Application Expired
Claire Lhuillier
Christian Beil
José Antonio Amengual Rigo
Yu Qiu
Xiangming Li
France
Germany
Germany
United States
United States
2023-12-1563610665AUTOMATED SCREENING FOR ACID SPHINGOMYELINASE DEFICIENCYGenzyme CorporationProvisional Application Expired
Alexandra Dumitriu
Maja Gašparic
Pauline Marie Guilmin
Martin Kristian Louis Montmerle
Stefaan Sansen
Neha B. Shah
United States
Netherlands
France
France
Belgium
United States
2023-12-1563610638ARTIFICIAL microRNAs TARGETING TAUGenzyme CorporationProvisional Application Expired
Bradford Miller ELMER
Jessica Marie HOGESTYN
Brenda RICHARDS
Shyam RAMACHANDRAN
United States
United States
United States
United States
2023-12-0818534085MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATIONGENZYME CORPORATIONPublications -- Issue Fee Payment VerifiedUS20240218051A1
Qun Zhou
Sunghae Park
Huawei Qiu
Marie-Priscille Brun
Francis Duffieux
United States
United States
United States
France
France
HUYNH, PHUONG N
2023-12-0763607419TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATIONGenzyme CorporationProvisional Application Expired
Matthew Adamowicz
Hao Chen
Amy Frederick
Christian Mueller
Catherine O'Riordan
Vaishnavi Rajagopal
John C. Reed
Michael John Storek
United States
United States
United States
United States
United States
United States
United States
United States
2023-12-0163605194IMAGE-BASED MOTOR FUNCTION ASSESSMENTGenzyme CorporationProvisional Application Expired
Hillol Sarker
Elena Gargaun
Qi Tang
United States
France
United States
2023-11-3063604675METHODS FOR TREATING DIGITALLY-IDENTIFIED CD20-RELATED DISORDERSGenzyme CorporationProvisional Application Expired
Cliona Marie Molony
United States
2023-11-2263602213PREDICTING PHARMACOKINETIC PROFILES OF CHEMICAL COMPOUNDS USING MACHINE LEARNINGGenzyme CorporationProvisional Application Expired
Alexandra Abos Ortega
Panteleimon D. Mavroudis
Nikhil S. Pillai
Spain
United States
United States
2023-11-2118515897PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTATGenzyme CorporationFinal Rejection MailedUS20240091208A1
Audrey JEANJEAN
Danielle COMBESSIS
David RIGAL
Chris HO
Pankaj TANEJA
France
France
France
United States
United States
TCHERKASSKAYA, OLGA V
2023-11-16PCTUS2023080062FLOCCULATION AAV PURIFICATIONGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
MAHSA HADIDI
BRUNO FIGUEROA
QINGXUAN LI
JUNFEN MA
YUANLI SONG
United States
United States
United States
United States
United States
2023-11-1618511501FLOCCULATION AAV PURIFICATIONGenzyme CorporationResponse to Non-Final Office Action Entered and Forwarded to ExaminerUS20240158761A1
Bruno Figueroa
Qingxuan Li
Junfen Ma
Yuanli Song
Mahsa Hadidi
United States
United States
United States
United States
United States
LY, KRISTINA ELISABETH
2023-11-1563599469METHODS OF TREATING NEURODEGENERATIVE DISORDERSGenzyme CorporationProvisional Application Expired
Shyam RAMACHANDRAN
United States
2023-11-1563599430METHODS OF TREATING GAUCHER DISEASE AND GBA-PARKINSON’S DISEASEGenzyme CorporationProvisional Application Expired
Swathi AYLOO
Shyam RAMACHANDRAN
United States
United States
2023-11-1318560569NOVEL PREDICTIVE BIOMARKERS FOR SECONDARY AUTOIMMUNITY AFTER LYMPHOCYTE DEPLETING THERAPYGENZYME CORPORATIONNon Final Action MailedUS20240254556A1
Darren Phillip BAKER
Emanuele DE RINALDIS
Richa HANAMSAGAR
Evis HAVARI
Virginia SAVOVA
Srinivas SHANKARA
United States
United States
United States
United States
United States
United States
HANEY, AMANDA MARIE
2023-11-09PCTUS2023079275COMPOSITION AND METHODS FOR CLEANINGGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
JOSEPH P. KUTZKO
United States
2023-10-31PCTUS2023036417SYSTEMS AND METHODS FOR MODELING THROMBIN-ANTITHROMBINGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
CHANCHALA KADDI
RANDOLPH LEISER
MENGDI TAO
SUSANA ZAPH
United States
United States
United States
United States
2023-10-1163589417TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHYGenzyme CorporationProvisional Application Expired
Seng Cheng
Sarah Melissa Jacobo
Takako Moriguchi
Catherine O'Riordan
Guoxiang Ruan
United States
United States
United States
United States
United States
2023-10-0918483474VARIANT RNAiGenzyme CorporationNon Final Action MailedUS20240182896A1
Lisa M. STANEK
Adam PALERMO
Brenda RICHARDS
Sergio Pablo SARDI
Catherine O'RIORDAN
Antonius SONG
United States
United States
United States
United States
United States
United States
CHONG, KIMBERLY
2023-10-06PCTUS2023034679METHODS OF OPTIMIZING DISSOLVED OXYGEN LEVELS IN CELL CULTUREGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
ETHAN DISSTON PENNER
CHARLES BUDDE
JEFFREY SWANA
United States
United States
United States
2023-10-06PCTUS2023034676PRODUCT FORMULATION IN BIOLOGICAL MANUFACTURINGGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
RITA BARRAL
MICHAEL COOLBAUGH
SUSHMITHA KRISHNAN
United States
United States
United States
2023-10-0663588586PREDICTING PHARMACOKINETIC PROFILES OF CHEMICAL COMPOUNDS USING MACHINE LEARNINGGenzyme CorporationProvisional Application Expired
Alexandra Abos Ortega
Panteleimon D. Mavroudis
Nikhil S. Pillai
Spain
United States
United States
2023-09-28PCTUS2023033980SYSTEMS AND DEVICES FOR PRODUCING BIOLOGICAL PRODUCTS AND METHODS OF USING THE SAMEGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
KEVIN BROWER
MICHAEL COOLBAUGH
XHORXHI GJOKA
CHAD VARNER
JASON WALTHER
United States
United States
United States
United States
United States
2023-09-2018470507METHODS FOR QUANTIFYING DRUG CONCENTRATION IN A PRODRUG COMPOSITIONGENZYME CORPORATIONNotice of Allowance Mailed -- Application Received in Office of PublicationsUS20240168035A1
Kim Alving
Bing Wang
United States
United States
ADAMS, MICHELLE
2023-09-1818282739SIZE EXCLUSION CHROMATOGRAPHY ANALYSIS OF EMPTY AND FULL AAV CAPSIDSGenzyme CorporationNon Final Action MailedUS20240159718A1
He MENG
United States
LI, BAO Q
2023-09-1563583228TREATMENT OF HEMOPHILIA A WITH FITUSIRANGenzyme CorporationProvisional Application Expired
Shauna Andersson
Salim Kichou
Sajida Iqbal
Laurel Menapace
Ekta Seth Chhabra
Viridiana Cano
Barbara Kittner
United States
France
United Kingdom
United States
United States
Mexico
United States
2023-09-0718463047HYPERGLYCOSYLATED BINDING POLYPEPTIDESGENZYME CORPORATIONNon Final Action MailedUS20240182595A1
Clark PAN
Huawei QIU
Pradeep DHAL
Bo CHEN
Diego GIANOLIO
United States
United States
United States
United States
United States
HUYNH, PHUONG N
2023-08-2863579111PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORSGenzyme CorporationProvisional Application Expired
John Ziqi Jiang
Sungtaek Lim
Gregory H. Merriman
Paul Justin Mueller
Sukanthini Thurairatnam
United States
United States
United States
United States
United States
2023-08-22PCTUS2023030770METHODS FOR TREATING RECEPTOR-INTERACTING PROTEIN KINASE 1-MEDIATED DISEASESGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
NAZEM ATASSI
CATHERINE CANTALLOUBE
AGNÈS HINCELIN-MERY
DONATO TEUTONICO
United States
France
France
France
2023-08-17PCTUS2023072366ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOFGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
MATTHIAS SCHIELL
ELISABETH DEFOSSA
UWE HEINELT
NILS RACKELMANN
MARIA MENDEZ PEREZ
HANS MATTER
NIELS GRIESANG
Germany
Germany
Germany
Germany
Germany
Germany
Germany
2023-08-1663519957AUTOMATED SCREENING FOR ACID SPHINGOMYELINASE DEFICIENCYGenzyme CorporationProvisional Application Expired
Alexandra Dumitriu
Maja Gašparic
Pauline Marie Guilmin
Martin Kristian Louis Montmerle
Stefaan Sansen
Neha B. Shah
United States
Netherlands
France
France
Belgium
United States
2023-08-1163532292DEVICES FOR CELL LYSIS AND METHODS OF USE THEREOFGenzyme CorporationProvisional Application Expired
Ethan Lovdal BUTLER
Mario G. JABRA
Junfen MA
Yuanli SONG
United States
United States
United States
United States
2023-07-1163513037TREATMENT OF CANCER WITH ANTI-ILT2 ANTIBODIESGENZYME CORPORATION
BIOND BIOLOGICS LTD.
Provisional Application Expired
Dana Haves Ziv
Liat Tevel
Enas Halumi
Nyra Goldstein
Tsuri Peretz
Ilana Goldshtein
Tal Gabay
Anna Fridam-Dror
Itay Friedman
Sharon Hashmueli
Motti Hakim
Ilana Mandel
Avidor Shulman
Yair Sapir
Tehila Ben-Moshe
Giovanni Abbadessa
Meijing Wu
Nigel Patrick Somerville Crawford
Rui Wang
Maria Agarwal
Cecilia Deantonio
Raymond Perez
Ji Lin
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
United States
United States
United States
United States
United Kingdom
United States
United States
2023-06-2763523428PROCESS FOR PREPARING 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILEGenzyme CorporationProvisional Application Expired
Jean-Pierre Leszczak
France
2023-06-21PCTUS2023025826SOLID FORMS OF DEUTERATED COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORSGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
PIERRE DEMONTIGNY
CRAIG S. SIEGEL
DONGLAI YANG
United States
United States
United States
2023-06-08PCTUS2023068143TREATMENT OF HEMOPHILIA WITH FITUSIRANGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
SHAUNA ANDERSSON
BAISONG MEI
FADI SHAMMAS
CHRISTIAN SUSSEBACH
United States
United States
Canada
Germany
2023-06-08PCTUS2023068137TREATMENT OF HEMOPHILIA WITH FITUSIRAN IN PEDIATRIC PATIENTSGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
SHAUNA ANDERSSON
PRATIK R R. BHAGUNDE
SAJIDA IQBAL
PRANAV PATEL
STACEY POLOSKEY
FADI SHAMMAS
United States
United States
United States
United States
United States
Canada
2023-06-0818331748Treatment of Hemophilia with FitusiranGenzyme CorporationNon Final Action MailedUS20240000744A1
Shauna Andersson
Baisong Mei
Fadi Shammas
Christian Sussebach
United States
United States
Canada
Germany
INAM, SAHAR
2023-06-0618256199TREATMENT OF HEMOPHILIA WITH FITUSIRANGenzyme CorporationNon Final Action MailedUS20240027478A1
Stacey Poloskey
Shauna Andersson
Pratik R. Bhagunde
Yue Cui
Sajida Iqbal
Baisong Mei
United States
United States
United States
United States
United States
United States
FAN, LYNN Y
2023-06-0563506245SLEEP-WAKE CLASSIFICATION USING MACHINE LEARNINGGenzyme CorporationProvisional Application Expired
Mikel Martinez Iparraguirre
Haneen Njoum
Hillol Sarkar
Elias Abou Zeid
Germany
Germany
United States
United States
2023-05-1718319279SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIESGenzyme CorporationResponse to Non-Final Office Action Entered and Forwarded to ExaminerUS20240059793A1
Luis AVILA
Clark PAN
Huawei QIU
Qun ZHOU
United States
United States
United States
United States
PUTTLITZ, KARL J
2023-05-15PCTUS2023067013METHODS OF TREATING METACHROMATIC LEUKODYSTROPHYGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
SHYAM RAMACHANDRAN
United States
2023-05-1518317772METHODS OF TREATING METACHROMATIC LEUKODYSTROPHYGenzyme CorporationResponse to Non-Final Office Action Entered and Forwarded to ExaminerUS20230398192A1
Shyam RAMACHANDRAN
United States
SHIBUYA, MARK LANCE
2023-05-1263502037PREDICTING MOTOR FUNCTION SCORES USING A BIOMARKERGenzyme CorporationProvisional Application Expired
Kristina An Haack
Rana Jreich
Zhaoling Meng
Fatiha Rachedi
Atef Zaher
France
France
United States
France
Canada
2023-05-1263502033PARKINSON'S TREMOR CLASSIFICATION USING MACHINE LEARNINGGenzyme CorporationProvisional Application Expired
Haneen Njoum
Hillol Sarker
Elias Abou Zeid
Germany
United States
United States
2023-05-1018315316FLOW CYTOMETRY ATTENUATED REPORTER EXPRESSION (FLARE) MULTIPLE REPORTER SYSTEM AND METHODS OF USE THEREOFGenzyme CorporationNon Final Action MailedUS20240035022A1
Victor R. Cairns
David Reczek
Jason Vitko
United States
United States
United States
PARISI, JESSICA DANIELLE
2023-04-2818141128INDUCTION OF IMMUNE TOLERANCE BY USING METHOTREXATEGenzyme CorporationFinal Rejection MailedUS20230372347A1
Alexandra JOSEPH
Susan RICHARDS
Melanie RUZEK
Richard GARMAN
United States
United States
United States
United States
LEE, CHIHYI NMN
2023-04-2663462212METHODS OF SCALING UP PRODUCTION OF rAAVGenzyme CorporationProvisional Application Expired
Kevin Victor Chen
Carlos Benitez
United States
United States
2023-04-2663462209METHODS OF IMPROVING rAAV PRODUCTIONGenzyme CorporationProvisional Application Expired
Srinivas Nellimarla
Jeong Lee
Ying Liu
United States
United States
United States
2023-04-1918303353MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATIONGENZYME CORPORATIONPublications -- Issue Fee Payment VerifiedUS20230391849A1
Qun Zhou
Sunghae Park
Huawei Qiu
Marie-Priscille Brun
Francis Duffieux
United States
United States
United States
France
France
HUYNH, PHUONG N
2023-04-1463459564METHODS OF TREATING METACHROMATIC LEUKODYSTROPHYGenzyme CorporationProvisional Application Expired
Shyam RAMACHANDRAN
United States
2023-04-12PCTUS2023065689USE OF AN IRAK4 MODULATOR FOR GENE THERAPYGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
SOURAV ROY CHOUDHURY
MONA MOTWANI
CHRISTIAN MUELLER
JOHN REED
United States
United States
United States
United States
2023-04-12PCTUS2023065688DENDRITIC CELL ASSAY FOR INNATE IMMUNOGENICITY TO GENE THERAPY AGENTSGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
SOURAV CHOUDHURY
MONA MOTWANI
United States
United States
2023-04-12PCTUS2023065687USE OF IRAK4 MODULATORS FOR GENE THERAPYGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
SOURAV ROY CHOUDHURY
MONA MOTWANI
CHRISTIAN MUELLER
JOHN REED
United States
United States
United States
United States
2023-04-1218299656DENDRITIC CELL ASSAY FOR INNATE IMMUNOGENICITY TO GENE THERAPY AGENTSGenzyme CorporationResponse to Non-Final Office Action Entered and Forwarded to ExaminerUS20230407255A1
Sourav Roy CHOUDHURY
Mona MOTWANI
United States
United States
SHIBUYA, MARK LANCE
2023-04-1218299640USE OF AN IRAK4 MODULATOR FOR GENE THERAPYGenzyme CorporationNon Final Action MailedUS20230405014A1
Sourav Roy CHOUDHURY
Mona MOTWANI
Christian MUELLER
John REED
United States
United States
United States
United States
KOSAR, ANDREW D
2023-04-1218299632USE OF IRAK4 MODULATORS FOR GENE THERAPYGenzyme CorporationNon Final Action MailedUS20230405151A1
Sourav Roy CHOUDHURY
Mona MOTWANI
Christian MUELLER
John REED
United States
United States
United States
United States
WHITEMAN, BRIAN A
2023-04-05PCTUS2023065388TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHYGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
SENG CHENG
SARAH MELISSA JACOBO
TAKAKO MORIGUCHI
CATHERINE O'RIORDAN
GUOXIANG RUAN
United States
United States
United States
United States
United States
2023-04-0563494453TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHYGenzyme CorporationProvisional Application Expired
Seng Cheng
Sarah Melissa Jacobo
Takako Moriguchi
Catherine O'Riordan
Guoxiang Ruan
United States
United States
United States
United States
United States
2023-04-0518296283TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHYGenzyme CorporationFinal Rejection MailedUS20230365968A1
Seng Cheng
Sarah Melissa Jacobo
Takako Moriguchi
Catherine O'Riordan
Guoxiang Ruan
United States
United States
United States
United States
United States
BRETZ, COREY LANE
2023-04-0363456658DEVICES FOR CELL LYSIS AND METHODS OF USE THEREOFGenzyme CorporationProvisional Application Expired
Ethan Lovdal BUTLER
Mario G. JABRA
Junfen MA
Yuanli SONG
United States
United States
United States
United States
2023-03-24PCTUS2023016181PROCESS FOR PREPARING SHP2 INHIBITORSGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
FABIO MORANA
DAVIDE GORNATI
JACOPO ROLETTO
Italy
Italy
Italy
2023-03-2018186731Pharmaceutical Recombinant Human Acid Sphingomyelinase Compositions and MethodsGenzyme CorporationDocketed New Case - Ready for ExaminationUS20230365946A1
Thomas M. Wasylenko
Kevin Brower
Xiaoying Jin
United States
United States
United States
IANNUZO, NATALIE NMN
2023-03-17PCTUS2023064657PHARMACEUTICAL RECOMBINANT HUMAN ACID SPHINGOMYELINASE COMPOSITIONS AND METHODSGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
THOMAS M. WASYLENKO
KEVIN BROWER
XIAOYING JIN
United States
United States
United States
2023-03-1663490736TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATIONGenzyme CorporationProvisional Application Expired
Matthew Adamowicz
Hao Chen
Amy Frederick
Christian Mueller
Catherine O'Riordan
Vaishnavi Rajagopal
John C. Reed
Michael John Storek
United States
United States
United States
United States
United States
United States
United States
United States
2023-03-1063489611TREATMENT OF HEMOPHILIA WITH FITUSIRANGenzyme CorporationProvisional Application Expired
Shauna Andersson
Baisong Mei
Fadi Shammas
Christian Sussebach
United States
United States
Canada
Germany
2023-03-1018025853COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASEGenzyme CorporationNotice of Allowance Mailed -- Application Received in Office of PublicationsUS20230348454A1
Kunal Desai
Zhong Fang
Kevin Guertin
Vu Hong
John Ziqi Jiang
Sungtaek Lim
Jinyu Liu
Mark Munson
United States
United States
United States
United States
United States
United States
United States
United States
HEASLEY, MEGHAN CHRISTINE
2023-03-1018025847CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASEGenzyme CorporationFinal Rejection MailedUS20230348450A1
Kunal Desai
Zhong Fang
Kevin Guertin
Vu Hong
John Ziqi Jiang
Sungtaek Lim
Mark Munson
United States
United States
United States
United States
United States
United States
United States
VAJDA, KRISTIN ANN
2023-03-0263449494NBD1 MODULATORS AND METHODS OF USING THE SAMEGenzyme Corporation
Sionna Therapeutics, Inc.
Provisional Application Expired
Junkai Liao
Mark Munson
Sukanthini Thurairatnam
Bradford Hirth
Zhongli Gao
Gregory Donald Hurlbut
Jinyu Liu
Michael Kothe
George Topalov
John E. Macor
Yi Li
Andrew Good
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
2023-03-0263449486NBD1 MODULATORS AND METHODS OF USING THE SAMEGenzyme Corporation
Sionna Therapeutics Inc.
Provisional Application Expired
Junkai Liao
Mark Munson
Sukanthini Thurairatnam
Bradford Hirth
Zhongli Gao
Gregory Donald Hurlbut
Jinyu Liu
Michael Kothe
George Topalov
John E. Macor
Yi Li
Andrew Good
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
2023-03-0263449472NBD1 MODULATORS AND METHODS OF USING THE SAMEGenzyme Corporation
Sionna Therapeutics Inc.
Provisional Application Expired
Junkai Liao
Mark Munson
Sukanthini Thurairatnam
Bradford Hirth
Zhongli Gao
Gregory Donald Hurlbut
Jinyu Liu
Michael Kothe
George Topalov
John E. Macor
Yi Li
Andrew Good
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
2023-03-0263449470NBD1 MODULATORS AND METHODS OF USING THE SAMEGenzyme Corporation
Sionna Therapeutics Inc.
Provisional Application Expired
Junkai Liao
Mark Munson
Sukanthini Thurairatnam
Bradford Hirth
Zhongli Gao
Gregory Donald Hurlbut
Jinyu Liu
Michael Kothe
George Topalov
John E. Macor
Yi Li
Andrew Good
David Borcherding
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
2023-02-24PCTUS2023013764METHODS OF PROCESSING A FLUIDGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
MICHAEL COOLBAUGH
SHASHI MALLADI
United States
United States
2023-02-2418174575METHODS OF PROCESSING A FLUIDGenzyme CorporationResponse to Non-Final Office Action Entered and Forwarded to ExaminerUS20230295224A1
Michael Coolbaugh
Shashi Malladi
United States
United States
LEBRON, BENJAMIN L
2023-02-1463445649AUTOMATED SCREENING FOR ACID SPHINGOMYELINASE DEFICIENCYGenzyme CorporationProvisional Application Expired
Alexandra Dumitriu
Maja Gasparic
Neha B. Shah
Stefaan Sansen
Pauline Marie Guilmin
Martin Kristian Louis Montmerle
United States
United States
United States
Belgium
France
France
2023-02-0763483700TREATMENT OF HEMOPHILIA WITH FITUSIRANGenzyme CorporationProvisional Application Expired
Shauna Andersson
Baisong Mei
Fadi Shammas
Christian Sussebach
United States
United States
Canada
Germany
2023-02-0363483075TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHYGenzyme CorporationProvisional Application Expired
Seng Cheng
Sarah Jacobo
Takako Moriguchi
Catherine O'Riordan
Guoxiang Ruan
United States
United States
United States
United States
United States
2023-01-3018007433METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAMEGENZYME CORPORATIONFinal Rejection MailedUS20230372313A1
Tanya Zaremba FISCHER
Judith PETERSCHMITT
United States
United States
SZNAIDMAN, MARCOS L
2023-01-2363440636DRUG FORMULATIONS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL) -3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILEGenzyme CorporationProvisional Application Expired
Jerome Arigon
Marilyn Calderone
Brigitte Illel
France
France
France
2023-01-1718155655SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGenzyme CorporationFinal Rejection MailedUS20230365965A1
Akin Akinc
Alfica Sehgal
Ivanka Toudjarska
Donald Foster
Stuart Milstein
Brian Bettencourt
Martin A. Maier
Klaus Charisse
Satyanarayana Kuchimanchi
Kallanthottathil G. Rajeev
Muthiah Manoharan
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
SHIN, DANA H
2023-01-1063479337TREATMENT OF HEMOPHILIA WITH FITUSIRANGenzyme CorporationProvisional Application Expired
Shauna Andersson
Baisong Mei
Fadi Shammas
Christian Sussebach
United States
United States
Canada
Germany